Compare Stocks → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:ABCNOTCMKTS:ATTBFOTCMKTS:CNBX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCNVIVO CannabisC$1.32+5.6%C$1.32C$0.80▼C$4.06C$256.62MN/A1.51 million shs310,601 shsATTBFAbattis Bioceuticals$0.00$0.00▼$0.00N/AN/A11,650 shs100,000 shsCNBXCNBX Pharmaceuticals$0.02$0.01$0.01▼$0.10N/AN/A260,014 shs10,208 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCNVIVO Cannabis0.00%0.00%0.00%0.00%0.00%ATTBFAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%CNBXCNBX Pharmaceuticals+13.57%+16.06%+25.20%+11.97%-33.47%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCNVIVO CannabisN/AN/AN/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACNBXCNBX PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCNVIVO CannabisN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/ACNBXCNBX PharmaceuticalsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCNVIVO CannabisN/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AN/ACNBXCNBX PharmaceuticalsN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCNVIVO CannabisN/AN/A0.00∞N/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/A-$0.16N/AN/AN/AN/AN/AN/AN/ACNBXCNBX PharmaceuticalsN/A-$0.01N/A∞N/AN/AN/AN/A4/14/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCNVIVO CannabisN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/ACNBXCNBX PharmaceuticalsN/AN/AN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCNVIVO CannabisN/AATTBFAbattis Bioceuticals32.45%CNBXCNBX Pharmaceuticals98.18%Insider OwnershipCompanyInsider OwnershipABCNVIVO CannabisN/AATTBFAbattis BioceuticalsN/ACNBXCNBX Pharmaceuticals73.51%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABCNVIVO CannabisN/A194.41 millionN/ANot OptionableATTBFAbattis BioceuticalsN/AN/AN/ANot OptionableCNBXCNBX Pharmaceuticals2N/AN/ANot OptionableCNBX, ATTBF, ABCN, ABZA, and AHZ HeadlinesSourceHeadlinePharmaceutical Sciences PhDbuffalo.edu - January 30 at 5:19 PMCNBX Pharmaceuticals Stock (OTC:CNBX) Dividends: History, Yield and Datesbenzinga.com - November 24 at 7:56 AMCNBX Pharmaceuticals Inc CNBXmorningstar.com - November 5 at 2:26 PMCNBX Historical Datainvesting.com - October 10 at 12:42 AMOther OTC Pharmaceuticals - Mongoliastatista.com - September 11 at 11:05 PMGlenmark Pharmaceuticals share pricelivemint.com - August 17 at 8:58 PMCNBX - CNBX Pharmaceuticals Inc.finance.yahoo.com - July 28 at 11:43 PMCNBX Acquires A Controlling Interest In Cancer Immunotherapy Developerbenzinga.com - November 8 at 3:58 PMCNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharmafinance.yahoo.com - November 8 at 10:56 AMCNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapyfinance.yahoo.com - October 18 at 6:19 PMCNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israelfinance.yahoo.com - October 13 at 11:58 AMCNBX Pharmaceuticals Announces New Patent Granted in Australiafinance.yahoo.com - September 28 at 10:12 AMCNBX Pharmaceuticals Increuters.com - September 12 at 10:07 PMCNBX Pharmaceuticals Inc. (CNBX)ca.finance.yahoo.com - August 16 at 8:20 PMCNBX Pharmaceuticals (OTC:CNBXD), Earnings Estimates, EPS, and Revenuebenzinga.com - June 10 at 9:56 AMCNBX Pharmaceuticals (OTC:CNBXD), Analyst Ratings, Price Targets, Predictionsbenzinga.com - June 10 at 9:56 AMCNBX Pharmaceuticals Inc. (CNBXD)finance.yahoo.com - June 7 at 9:09 PMCNBX Pharmaceuticals Release a New Corporate Presentationfinance.yahoo.com - May 31 at 11:31 AMCNBX Pharmaceuticals Inc.barrons.com - May 14 at 9:19 PMCNBX pharma granted patent in Hong Kong for cancer therapyseekingalpha.com - May 5 at 2:39 PMCNBX Pharmaceuticals Granted Patent in Hong Kongfinance.yahoo.com - May 5 at 9:26 AMSuven acquires Casper Pharma; expect product boost, says CMD Venkat Jasticnbctv18.com - April 5 at 12:46 PMNovartis to save at least $1 billion by 2024 thanks to simplified structuremsn.com - April 4 at 6:24 PMVertex Pharma sees positive results in Phase 2 trials of new non-opioid pain killermsn.com - April 4 at 6:24 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsVIVO CannabisCVE:ABCNABcann Global Corporation manufactures and distributes medical cannabis. The company is headquartered in Napanee, Canada.Abattis BioceuticalsOTCMKTS:ATTBFAbattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.CNBX PharmaceuticalsOTCMKTS:CNBXCNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.